Vaping abstinence rates
The cotinine level-verified CARs for weeks 4–12 and weeks 4–24 are shown in Fig. Efficacy CAR. Proportion of participants who reported abstinence from vaping, which was defined by cotinine level-verified self-reported abstinence. Primary efficacy end point was the continuous abstinence rate at weeks 4 to 12Continuous abstinence rates and 7-day point prevalenceThe 7-day point prevalence of vaping abstinence was also higher for the varenicline than placebo at each time point (Table Of note, none of the factors that were found to be significantly different at baseline (i.e. age, BAI, PSECDI, and education level) contributed to the effect of varenicline on CAR for weeks 4–12 (see Additional file 